THE first in a new class of
medicine that reduces the strain
on failing hearts and the risk
of cardiovascular death and
hospitalisation from systolic heart
failure compared to angiotensin
converting enzyme (ACE) inhibitor
therapy can now be prescribed in
Australia.
The new drug is Entresto
(sacubitril/valsartan) from Novartis,
an angiotensin receptor neprilsyn
inhibitor (ARNI), approved for
use in adults for the treatment of
chronic heart failure (NYHA Class IIIV)
with reduced ejection fraction.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Feb 16
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.